The Medicines (MDCO)

Add to Watchlists
Create an Alert
24.55 -0.35  -1.41% NASDAQ Apr 17, 8:00PM BATS Real time Currency in USD
View Full Chart
MDCO Price Chart
View All Events

MDCO Events

Date Type Description
Apr 23 Misc Q1 2014 the Medicines Company Earnings Conference Call
Apr 23 Earnings Q1 2014 the Medicines Company Earnings Results. Estimate: -0.13.
Mar 07 Misc The Medicines Company to Host Acute Cardiovascular Care Investor and Analyst Meeting
Feb 19 Misc Medicines Q4 2013 Earnings Conference Call
Feb 19 Earnings Medicines Q4 2013 Earning Result. Estimate: 0.14.
Dec 04 Misc The Medicines Company Acquires Rempex Pharmaceuticals
Oct 23 Misc Q3 2013 the Medicines Company Earnings Conference Call
Oct 23 Earnings The Medicines Company to Announce Third Quarter 2013 Financial Results on Wednesday, October 23, 2013. Estimate: 0.24.
Jul 24 Misc Q2 2013 the Medicines Company Earnings Conference Call
Jul 24 Earnings The Medicines Company to Announce Second Quarter and First Half 2013 Financial Results on Wednesday, July 24, 2013. Estimate: 0.31.
View All Performance Charts

MDCO Total Returns Comparison

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). The Medicines is down 26.34% over the last year vs S&P 500 Total Return up 20.96%, Gilead Sciences up 34.77%, and Hospira up 36.91%.

Get Quote for

PDF Report for MDCO

Download Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.

Download MDCO Pro Report PDF
Advertisement

Portfolio Strategies Featuring MDCO

Did The Medicines make it into our Portfolio Strategies?
Start your YCharts membership now to find out.

MDCO Profile

  • Sector: Healthcare
  • Industry: Drug Manufacturers - Specialty & Generic
  • Headquarters Country: United States
  • Headquarters State/Province: New Jersey
  • Incorporation Country: United States
  • Incorporation State/Province: Delaware
  • Est. Current Fiscal Quarter End: June 30, 2014
  • Est. Current Fiscal Year End: December 31, 2014
  • Last Fiscal Quarter End: N/A
  • Last Fiscal Year End: N/A
  • NAICS: Pharmaceutical Preparation Manufacturing
  • NAICS Code: 325412
  • NAICS Industry: Pharmaceutical and Medicine Manufacturing
  • NAICS Industry Code: 3254
  • NAICS Sector: Manufacturing
  • NAICS Sector Code: 32

The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. The Company markets Angiomax® (bivalirudin) in the United States and other countries for use in patients undergoing coronary angioplasty, and Cleviprex® (clevidipine butyrate) injectable emulsion in the United States for the reduction of blood pressure when oral therapy is not feasible or not desirable. The Company also has an investigational antiplatelet agent, cangrelor, in late-stage development and a serine protease inhibitor, CU2010, in early-stage development. Through the acquisition of Targanta Therapeutics Corporation, The Medicines Company’s pipeline also includes oritavancin, a semi-synthetic lipoglycopeptide antibiotic in late-stage development in the United States. The Medicines Company was founded by Clive A. Meanwell and T. Scott Johnson on July 31, 1996 and is headquartered in Parsippany, New Jersey.

Recent Quotes

Symbol Price Chg Chg % Market Cap
MDCO 24.55 -0.35 -1.41% 1.588B
Create Watchlist from Quotes
Advertisement

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

required
required
required
required
required
Get Started Now
document.write('');

{{root.upsell.info.feature_headline}}.
Upgrade to {{root.upsell.info.tier_name}}. Start Your YCharts Membership. Start your {{root.upsell.info.tier_name}} Membership

{{root.upsell.info.feature_description}}

{{root.upsell.info.is_upgrade ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{root.upsell.info.tier_name}} Member? Sign in here.